Abstract
Cardiovascular diseases are not only the most common non-communicable diseases, but also occupy the leading place in the structure of total mortality in the world population. Among the wide range of pathogenetic mechanisms of the above-mentioned pathology, an increase in the activity of the sympathetic nervous system should be marked, given that catestatin, known primarily for its ability to inhibit hyperactivation of the sympathetic nervous system, deserves special attention. This article considers the issue of the diagnostic potential of catestatin in the management of cardiovascular pathology. The literature analysis made it possible to determine the dynamics of catestatin levels during the development of coronary heart disease and heart failure. The established correlations of catestatin with other cardiovascular biomarkers, such as NT-proBNP, sST2, hscTnI, allow us to note its potential place in the diagnosis of cardiovascular pathology. The results of numerous clinical studies demonstrated the correlation between catestatin levels and the development of complications, including the level of mortality, which allows considering catestatin as a predictor of the development of complications of cardiovascular diseases. Therefore, the prognostic value of catestatin levels in patients with coronary heart disease and heart failure allows it to be considered a marker of these diseases.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Reference34 articles.
1. 1. Malakar A, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. Journal of Cellular Physiology. 2019;234(10):16812-16823. http://dx.doi.org/10.1002/jcp.28350
2. 2. Bozic J, Kumric M, Ticinovic Kurir T, Urlic H, Martinovic D, Vilovic M, Tomasovic Mrcela N, Borovac J. Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective. Biomedicines. 2021;9(12):1757. http://dx.doi.org/10.3390/biomedicines9121757
3. 3. Pankova OA. Katestatyn yak rehulyator aktyvnosti sympatychnoyi nervovoyi systemy ta joho vplyv na rozvytok i prohresuvannya hipertonichnoyi xvoroby ta cukrovoho diabetu 2 typu. Problemy bezperervnoyi medychnoyi osvity ta nauky. 2021;2 (42):49-54. doi: 10.31071/ promedosvity2021.02.049. Ukrainian
4. 4. Bourebaba Y, Mularczyk M, Marycz K, Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomedicine & Pharmacotherapy. 2021;134:111113. http://dx.doi.org/10.1016/j.biopha.2020.111113
5. 5. Pankova OA. Rol" katestatynu u rehulyaciyi metabolichnyx rozhlyadiv. Ohlyad // Medychna nauka Ukrayiny. 2022;18(2):69-78. doi: 10.32345/2664-4738.2.2022.09. Ukrainian
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献